Business Context and Reporting Period
This Form 8-K Current Report was filed by Glaukos Corporation (GKOS) on March 12, 2020. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Dr. Gilbert H. Kliman, M.D., as a Class I director effective March 12, 2020. Dr. Kliman was also appointed to the Compensation Committee. He will serve until the 2022 annual meeting of stockholders. This appointment follows his previous tenure on the Board from 2007 until August 2019.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations. Regarding the appointment, the Board confirmed there are no arrangements or understandings between Dr. Kliman and any other person that influenced his appointment, and he holds no direct or indirect material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K. Dr. Kliman will receive compensation in accordance with the Company's standard program for non-employee directors and will enter into a standard indemnity agreement.
Investor Verification Checklist
- Verify Dr. Kliman's compensation structure by reviewing Exhibit 10.25 of the Company's Annual Report on Form 10-K filed on March 2, 2020.
- Review the standard indemnity agreement filed as Exhibit 10.4 to the March 2, 2020 Form 10-K.
- Confirm Dr. Kliman's independence and lack of material interests in transactions as stated in the filing.
- Note that this filing does not update financial results; refer to the most recent 10-K or 10-Q for financial metrics.